Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel.

Willis J, Lefterova MI, Artyomenko A, Kasi PM, Nakamura Y, Mody K, Catenacci DVT, Fakih M, Barbacioru C, Zhao J, Sikora M, Fairclough SR, Lee H, Kim KM, Kim ST, Kim J, Gavino D, Benavides M, Peled N, Nguyen T, Cusnir M, Eskander RN, Azzi G, Yoshino T, Banks KC, Raymond VM, Lanman RB, Chudova DI, Talasaz A, Kopetz S, Lee J, Odegaard JI.

Clin Cancer Res. 2019 Aug 4. doi: 10.1158/1078-0432.CCR-19-1324. [Epub ahead of print]

PMID:
31383735
2.

Development and analytical validation of a next-generation sequencing based microsatellite instability (MSI) assay.

Pabla S, Andreas J, Lenzo FL, Burgher B, Hagen J, Giamo V, Nesline MK, Wang Y, Gardner M, Conroy JM, Papanicolau-Sengos A, Morrison C, Glenn ST.

Oncotarget. 2019 Aug 27;10(50):5181-5193. doi: 10.18632/oncotarget.27142. eCollection 2019 Aug 27.

3.

A Novel and Reliable Method to Detect Microsatellite Instability in Colorectal Cancer by Next-Generation Sequencing.

Zhu L, Huang Y, Fang X, Liu C, Deng W, Zhong C, Xu J, Xu D, Yuan Y.

J Mol Diagn. 2018 Mar;20(2):225-231. doi: 10.1016/j.jmoldx.2017.11.007. Epub 2017 Dec 19.

PMID:
29277635
4.

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non-small Cell Lung Cancer.

Leighl NB, Page RD, Raymond VM, Daniel DB, Divers SG, Reckamp KL, Villalona-Calero MA, Dix D, Odegaard JI, Lanman RB, Papadimitrakopoulou VA.

Clin Cancer Res. 2019 Aug 1;25(15):4691-4700. doi: 10.1158/1078-0432.CCR-19-0624. Epub 2019 Apr 15.

PMID:
30988079
5.

Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data.

Middha S, Zhang L, Nafa K, Jayakumaran G, Wong D, Kim HR, Sadowska J, Berger MF, Delair DF, Shia J, Stadler Z, Klimstra DS, Ladanyi M, Zehir A, Hechtman JF.

JCO Precis Oncol. 2017;2017. doi: 10.1200/PO.17.00084. Epub 2017 Oct 3.

6.

Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.

Vanderwalde A, Spetzler D, Xiao N, Gatalica Z, Marshall J.

Cancer Med. 2018 Mar;7(3):746-756. doi: 10.1002/cam4.1372. Epub 2018 Feb 13. Erratum in: Cancer Med. 2018 Jun;7(6):2792.

7.

Microsatellite instability in prostate cancer by PCR or next-generation sequencing.

Hempelmann JA, Lockwood CM, Konnick EQ, Schweizer MT, Antonarakis ES, Lotan TL, Montgomery B, Nelson PS, Klemfuss N, Salipante SJ, Pritchard CC.

J Immunother Cancer. 2018 Apr 17;6(1):29. doi: 10.1186/s40425-018-0341-y.

8.

Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade.

Georgiadis A, Durham JN, Keefer LA, Bartlett BR, Zielonka M, Murphy D, White JR, Lu S, Verner EL, Ruan F, Riley D, Anders RA, Gedvilaite E, Angiuoli S, Jones S, Velculescu VE, Le DT, Diaz LA Jr, Sausen M.

Clin Cancer Res. 2019 Sep 10. doi: 10.1158/1078-0432.CCR-19-1372. [Epub ahead of print]

PMID:
31506389
9.

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability (MSI) and Pan-Tumor Characterization of One Thousand MSI-High Cases in 67,000 Patient Samples.

Trabucco SE, Gowen K, Maund SL, Sanford E, Fabrizio DA, Hall MJ, Yakirevich E, Gregg JP, Stephens PJ, Frampton GM, Hegde PS, Miller VA, Ross JS, Hartmaier RJ, Huang SA, Sun JX.

J Mol Diagn. 2019 Aug 21. pii: S1525-1578(19)30358-7. doi: 10.1016/j.jmoldx.2019.06.011. [Epub ahead of print]

10.

Detection of somatic mutations in cell-free DNA in plasma and correlation with overall survival in patients with solid tumors.

Mehrotra M, Singh RR, Loghavi S, Duose DY, Barkoh BA, Behrens C, Patel KP, Routbort MJ, Kopetz S, Broaddus RR, Medeiros LJ, Wistuba II, Luthra R.

Oncotarget. 2017 Oct 24;9(12):10259-10271. doi: 10.18632/oncotarget.21982. eCollection 2018 Feb 13.

11.

Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort.

Lee J, Franovic A, Shiotsu Y, Kim ST, Kim KM, Banks KC, Raymond VM, Lanman RB.

Front Oncol. 2019 Apr 4;9:212. doi: 10.3389/fonc.2019.00212. eCollection 2019.

12.

Accurate Pan-Cancer Molecular Diagnosis of Microsatellite Instability by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing.

Waalkes A, Smith N, Penewit K, Hempelmann J, Konnick EQ, Hause RJ, Pritchard CC, Salipante SJ.

Clin Chem. 2018 Jun;64(6):950-958. doi: 10.1373/clinchem.2017.285981. Epub 2018 Apr 9.

13.

Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.

Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, Tran C, Stewart C, Sheehan M, Penson A, DeLair D, Yaeger R, Vijai J, Mukherjee S, Galle J, Dickson MA, Janjigian Y, O'Reilly EM, Segal N, Saltz LB, Reidy-Lagunes D, Varghese AM, Bajorin D, Carlo MI, Cadoo K, Walsh MF, Weiser M, Aguilar JG, Klimstra DS, Diaz LA Jr, Baselga J, Zhang L, Ladanyi M, Hyman DM, Solit DB, Robson ME, Taylor BS, Offit K, Berger MF, Stadler ZK.

J Clin Oncol. 2019 Feb 1;37(4):286-295. doi: 10.1200/JCO.18.00283. Epub 2018 Oct 30. Erratum in: J Clin Oncol. 2019 Apr 10;37(11):942.

14.

Using circulating cell-free DNA to monitor personalized cancer therapy.

Oellerich M, Sch├╝tz E, Beck J, Kanzow P, Plowman PN, Weiss GJ, Walson PD.

Crit Rev Clin Lab Sci. 2017 May;54(3):205-218. doi: 10.1080/10408363.2017.1299683. Epub 2017 Apr 10. Review.

PMID:
28393575
15.

Detection of Microsatellite Instability Biomarkers via Next-Generation Sequencing.

Bonneville R, Krook MA, Chen HZ, Smith A, Samorodnitsky E, Wing MR, Reeser JW, Roychowdhury S.

Methods Mol Biol. 2020;2055:119-132. doi: 10.1007/978-1-4939-9773-2_5.

PMID:
31502149
16.

Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.

Hovelson DH, Liu CJ, Wang Y, Kang Q, Henderson J, Gursky A, Brockman S, Ramnath N, Krauss JC, Talpaz M, Kandarpa M, Chugh R, Tuck M, Herman K, Grasso CS, Quist MJ, Feng FY, Haakenson C, Langmore J, Kamberov E, Tesmer T, Husain H, Lonigro RJ, Robinson D, Smith DC, Alva AS, Hussain MH, Chinnaiyan AM, Tewari M, Mills RE, Morgan TM, Tomlins SA.

Oncotarget. 2017 Sep 22;8(52):89848-89866. doi: 10.18632/oncotarget.21163. eCollection 2017 Oct 27.

17.

Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.

Janku F, Zhang S, Waters J, Liu L, Huang HJ, Subbiah V, Hong DS, Karp DD, Fu S, Cai X, Ramzanali NM, Madwani K, Cabrilo G, Andrews DL, Zhao Y, Javle M, Kopetz ES, Luthra R, Kim HJ, Gnerre S, Satya RV, Chuang HY, Kruglyak KM, Toung J, Zhao C, Shen R, Heymach JV, Meric-Bernstam F, Mills GB, Fan JB, Salathia NS.

Clin Cancer Res. 2017 Sep 15;23(18):5648-5656. doi: 10.1158/1078-0432.CCR-17-0291. Epub 2017 May 23.

18.

An Accurate and Comprehensive Clinical Sequencing Assay for Cancer Targeted and Immunotherapies.

Cao J, Chen L, Li H, Chen H, Yao J, Mu S, Liu W, Zhang P, Cheng Y, Liu B, Hu Z, Chen D, Kang H, Hu J, Wang A, Wang W, Yao M, Chrin G, Wang X, Zhao W, Li L, Xu L, Guo W, Jia J, Chen J, Wang K, Li G, Shi W.

Oncologist. 2019 Aug 13. pii: theoncologist.2019-0236. doi: 10.1634/theoncologist.2019-0236. [Epub ahead of print]

PMID:
31409745
19.

Microsatellite Instability and Altered Expressions of MLH1 and MSH2 in Gastric Cancer

Haron NH, Mohamad Hanif EA, Abdul Manaf MR, Yaakub JA, Harun R, Mohamed R, Mohamed Rose I.

Asian Pac J Cancer Prev. 2019 Feb 26;20(2):509-517.

20.

[Value of detection of DNA mismatch repair proteins deficiency by immunohistochemistry in predicting tumor microsatellite status].

Qin Y, Liang L, Zheng X, Zheng J, Ye J, Guo L, Zhao F, Shi X.

Zhonghua Bing Li Xue Za Zhi. 2015 Oct;44(10):704-8. Chinese.

PMID:
26702526

Supplemental Content

Support Center